Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Has Consensus Price Target of $4.75

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have earned an average rating of “Hold” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $4.75.

A number of research firms recently commented on IPSC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a research note on Tuesday, September 29th. Wall Street Zen raised Century Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th.

Century Therapeutics Trading Down 2.0%

Century Therapeutics stock opened at $1.44 on Tuesday. Century Therapeutics has a 52 week low of $0.43 and a 52 week high of $3.04. The stock has a market cap of $260.74 million, a price-to-earnings ratio of -1.55 and a beta of 1.67. The company’s 50-day moving average price is $1.88 and its two-hundred day moving average price is $2.12.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). Research analysts expect that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Century Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IPSC. Versant Venture Management LLC acquired a new position in shares of Century Therapeutics during the 1st quarter valued at $27,495,000. BlackRock Inc. acquired a new stake in shares of Century Therapeutics in the second quarter valued at $19,825,000. Commodore Capital LP bought a new position in Century Therapeutics during the first quarter valued at about $19,652,000. Seven Fleet Capital Management LP bought a new position in Century Therapeutics during the second quarter valued at about $10,652,174. Finally, Trails Edge Capital Partners LP bought a new position in Century Therapeutics during the second quarter valued at about $10,130,674. 50.20% of the stock is owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc (NASDAQ:IPSC) is a biotechnology company developing allogeneic cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create potentially scalable immune-cell products designed to treat patients without relying on cells collected from each individual patient.

Century’s research focuses primarily on iPSC-derived natural killer (NK) cells and T cells that are genetically engineered to recognize and attack cancer cells. Its pipeline has included investigational chimeric antigen receptor (CAR) cell therapies targeting blood cancers, including B-cell malignancies, with the goal of providing readily available, “off-the-shelf” treatments.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics conducts research and development activities in the United States.